Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II (Q28299468)

2

0 references

Jing Pan

3

0 references

Joseph Muenzer

4

0 references

Justin C Lamsa

Molecular Genetics and Metabolism

5

0 references

language of work or name

English

0 references

publication date

June 2007

0 references

published in

0 references

volume

91

0 references

page(s)

183-90

0 references

issue

2

0 references

cites work

Molecular analysis in 23 Hunter disease families

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Molecular and phenotypic variation in patients with severe Hunter syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

The Relative Frequency of the Hurler and Hunter Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Prevalence of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Incidence of Hunter's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

The frequency of lysosomal storage diseases in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Cumulative incidence rates of the mucopolysaccharidoses in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme-replacement therapy in mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Enzyme replacement therapy for murine mucopolysaccharidosis type VII

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

Mild form of Hunter's syndrome: clinical delineation based on 31 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.03.003